India's Expert Group Says Denying Patents To Incremental Innovations Will Not Be TRIPS-Compliant; Evergreening To Be Scrupulously Prevented
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Putting to rest wide speculation about applicability of the controversial Section 3 (d) of the Indian Patents Act, which deals with the treatment of incremental innovations, the Mashelkar Committee report - set up to dwell on Indian patent law issues - has recommended that incremental innovations should be encouraged